The NDA submission is supported by data from a phase 1 trial which demonstrated that 32mg of HTX-019 as a 30-second IV injection was bioequivalent to oral aprepitant 40mg for the prevention of PONV.

Cite this: Monoclonal Antibodies for COVID – Give IV Infusion or an Injection? - Medscape - Apr 13, 2022. Authors and Disclosures. Authors and Disclosures Journalist Randy Dotinga.

FDA has approved Cubist Pharmaceuticals’ marketed antibiotic, Cubicin®, for once-a-day dosing as a two-minute intravenous (IV) injection. Several other changes were also made to the Cubicin label.